07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

ECCS-50: Completed Phase II enrollment

Bimini’s Kerastem Technologies LLC company completed enrollment of 70 patients in the double-blind, sham-controlled, U.S. Phase II STYLE trial evaluating 500,000 and 1 million/cm 2 subcutaneous ADRCs. Cytori granted Bimini exclusive, worldwide rights to the...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

Cytori, Lorem Vascular Pty. Ltd. sales and marketing update

Cytori granted newco Lorem exclusive rights to commercialize Cytori's Celution System for autologous re-implantation or re-infusion of a patient's adipose-derived regenerative cells for all indications, excluding alopecia and aesthetics, in China, Malaysia and Australia. Cytori...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Clinical News

Celution System regulatory update

Singapore's Health Sciences Authority (HSA) approved Cytori's Celution System for autologous re-implantation or re-infusion of a patient's adipose-derived regenerative cells. The point-of-care system can be used to treat a variety of conditions, including soft tissue...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Clinical News

Celution System regulatory update

The Australia's Therapeutic Goods Administration ( TGA ) approved Cytori's Celution System for autologous re-implantation or re-infusion of a patient's adipose-derived regenerative cells to treat a variety of conditions, particularly in the area of soft...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Company News

Bimini Technologies, Cytori deal

Cytori entered into a three-part deal with Bimini, a newco focused on global aesthetics market, related to its Puregraft and Celution products. Cytori divested to Bimini its assets related to Cytori's Puregraft product line in...